CRESCENT BIOPHARMA INC (CBIO) Stock Analyst Ratings
USA - NASDAQ:CBIO - KYG2545C1042 - Common Stock
12.8 USD
+0.3 (+2.4%)
12.8 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 86% to CBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 26.01. This target is 103.2% above the current price.
CBIO was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CBIO.
In the previous month the buy percentage consensus was at a similar level.
CBIO was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-25 | Jefferies | Initiate | Buy |
| 2025-08-11 | HC Wainwright & Co. | Initiate | Buy |
| 2025-07-14 | Wedbush | Initiate | Outperform |
| 2025-06-25 | Stifel | Initiate | Buy |
| 2025-06-18 | LifeSci Capital | Initiate | Outperform |
| 2021-11-15 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2021-08-06 | Raymond James | Maintains | Outperform |
| 2021-04-29 | Raymond James | Maintains | Outperform |
| 2021-02-10 | Piper Sandler | Initiate | Overweight |